Regencell Bioscience Shares Down 6.8% to $22.67
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Regencell Bioscience is down -6.8%, or -$1.65 to $22.67.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like RCEL with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on RCEL
Wall Street analysts forecast RCEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 4.25 USD with a low forecast of 3.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.440
Low
3.00
Averages
4.25
High
5.50
Current: 4.440
Low
3.00
Averages
4.25
High
5.50
About RCEL
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations
- Soleno Stock Decline: Following a report from Scorpion Capital labeling Soleno Therapeutics' Vykat XR as overpriced and potentially unsafe for children, the stock plummeted by 7.41% to close at $71.63 on August 15, 2025, indicating significant market concerns regarding product safety.
- Avita Financial Struggles: Avita Medical revealed a backlog of unpaid claims affecting demand for its Recell product in its Q2 2025 report, leading to a 21% drop in stock price to $4.25 on August 8, 2025, highlighting major challenges in medical claims management.
- Coty's Disappointing Performance: Coty reported an unexpected loss and provided disappointing guidance for FY 2025, resulting in a 21.6% decline in stock price to $3.81 on August 21, 2025, reflecting broader market challenges and shifts in consumer behavior impacting sales.
- Legal Investigation Impact: Bragar Eagel & Squire is investigating potential federal securities law violations by these three companies, which could lead to further legal and financial repercussions, necessitating investor vigilance regarding future developments to assess potential risks.
Continue Reading
AVITA Medical Appoints Joe Woody as Board Director, Lou Panaccio Retires
- New Board Appointment: AVITA Medical announces the appointment of Joe Woody as a new non-executive director, bringing over 20 years of leadership experience in the med-tech sector, which will be crucial for the company's growth trajectory.
- Leadership Transition: Lou Panaccio retires after over a decade of service, having served as Chairman and significantly shaped the company's commercial and operational strategies, ensuring stability in the market.
- Rich Industry Experience: Joe Woody's previous roles include CEO of Avanos Medical and executive positions at Acelity Holdings, enhancing the board's depth of expertise with his extensive background in the industry.
- Strategic Value Enhancement: The addition of the new director not only strengthens AVITA Medical's leadership team but also supports the company's innovation and market expansion in acute wound care solutions.
Continue Reading